Taste Meets Science: Natures Aid Launches NSF-Certified Creatine Gummy

HONG KONG, Feb. 3, 2026 /PRNewswire/ -- Creatine has long been a staple supplement for athletes and active individuals, but traditional formats such as powders, capsules, and tablets often come with trade-offs related to taste, preparation, and convenience. In response to these limitations, Natures Aid has introduced a gummy-based creatine supplement designed to combine verified formulation standards with a more accessible and enjoyable consumption experience.

The Natures Aid NSF Certified Creatine Gummy represents a new approach to creatine delivery, built around the principle that effectiveness and ease of use should work together. Developed with a strong focus on formulation integrity and manufacturing quality, the product is positioned as the world's first Natures Aid creatine gummy created to achieve a carefully balanced combination of taste and potency.

Formulation Approach and Production Technology

Developing a creatine gummy presents unique formulation challenges, particularly when it comes to preserving ingredient stability while achieving a consistent texture. Natures Aid addresses this through its strategic partnership with SUCOTOND, a manufacturing specialist known for its proprietary "zero-grain" technology. 

The zero-grain technology supports uniform texture and content, contributing to a smooth, chewable consistency without the graininess sometimes associated with gummy supplements. This approach ensures that each gummy delivers consistent creatine content while maintaining a palatable mouthfeel.

In addition to texture control, Natures Aid incorporates a cold-processing method during production. This technique is designed to help retain creatine integrity by minimizing exposure to high temperatures that may affect ingredient stability. Together, these processes form the scientific foundation of the creatine gummy, aligning manufacturing precision with consumer-friendly design.

NSF Certification and Manufacturing Standards

Quality assurance is a central element of the product's development. The gummies are NSF 173 certified, reflecting compliance with recognized standards related to ingredient verification, safety, and manufacturing practices. NSF certification is widely used within the supplement industry as an indicator of quality, particularly for products intended for active and performance-focused users.

Natures Aid reports that the gummies are manufactured, tested, and bottled in a GMP-certified facility. This manufacturing environment is intended to support batch-to-batch consistency and quality control throughout the production process.

Supporting Performance and Usage Format

Natures Aid positions its creatine gummies as a convenient way to support muscle strength, muscle recovery, endurance, and daily energy needs. Rather than emphasizing short-term outcomes, the product is framed as a consistent supplement option designed to complement an active lifestyle over time.

Each serving of Natures Aid creatine gummies delivers 5g=3 of pure creatine monohydrate, provided in 3 gummies per serving. Each bottle contains 135 gummies and is formulated to meet a wide range of dietary preferences. 

The gummies are designed for flexible daily use and can be taken at any time of day. This convenience allows users to integrate creatine supplementation into their routines at home, at work, or while traveling. Athletes and fitness enthusiasts may incorporate it into structured training and recovery routines, while busy professionals may appreciate its quick and portable format during demanding schedules.

A New Direction in Creatine Delivery

As the supplement market evolves, the delivery format has become an important factor alongside ingredient selection. Natures Aid's approach reflects a broader shift toward products that balance certification, manufacturing integrity, and everyday usability. By combining NSF certification, GMP-compliant manufacturing, and specialized production technologies, the brand introduces a new standard for gummy-based creatine supplements.

Learn more about Natures Aid NSF Certified Creatine Gummy.

About Natures Aid

Natures Aid is a nutritional supplement brand focused on developing products that combine verified formulation standards with practical delivery formats. The company emphasizes quality assurance, certified manufacturing processes, and ingredient transparency across its product portfolio. 

Contact Info:

Company name: Natures Aid

Contact Person: WANDAN

Email: vipnaturesaid@hotmail.com 

Country & City: HongKong, China

Website: https://www.amazon.com/Natures-Aid-Creatine-Monohydrate-Gummies/dp/B0F3JBGGGZ?th=1 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Taste Meets Science: Natures Aid Launches NSF-Certified Creatine Gummy

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.

Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.

To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).

Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.

Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.

The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.

Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.

This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.

These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.

Media Contact: 

Chi Zhang
media@westlake.edu.cn 
+86-15659837873

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform